FDA Advisory Panel to Vote on Composition of Covid-19 Vaccines for 2026-2027
Key Takeaways
- VRBPAC is evaluating an XFG-targeted composition for 2026–2027 vaccines, based on CDC variant prevalence estimates that are more than a month old.
- FDA briefing materials emphasize eroding sequencing throughput and lagging state/local data sharing, impairing real-time assessment of SARS-CoV-2 evolution.
FDA advisors are set to meet this week to determine whether Covid-19 vaccines should be updated to target the emerging XFG variant, a decision that could shape the composition of the 2026–2027 immunization season amid ongoing viral evolution.
The FDA's vaccine advisory panel is meeting to vote on the composition of Covid-19 vaccines for the 2026-2027 immunization season.
The vote will have staff and scientific advisers weighing a recommendation to target the dominant XFG variant amid significant gaps in the surveillance data used to inform the decision.
As of May 28, 2026, just four Covid vaccines are currently approved for use in the U.S.: Moderna's mNEXSPIKE and Spikevax, Pfizer-BioNTech's Comirnaty, and Novavax-Sanofi's protein-based vaccine.2
What is the panel being asked to decide?
The Vaccines and Related Biological Products Advisory Committee is convening to determine whether Covid-19 vaccines for the upcoming season should be updated to target XFG, the variant currently accounting for more than half of U.S. cases based on the most recent available data, according to the most recent CDC update, which is more than a month old.1 The panel is meeting with its existing membership intact, a procedural signal of normalcy following months of turbulence in vaccine policy under Health Secretary Robert F. Kennedy Jr., which saw a
What are the key concerns going into the vote?
Prior to the meeting, FDA staff raised concerns in briefing documents about the limited and deteriorating quality of data on currently circulating strains. The agency said assessing Covid-19's evolution has become increasingly difficult as virologic surveillance, sequencing volumes, and timely data sharing from state and local public health departments have declined.1 The CDC's Covid dashboard reflects the gap directly as weekly data is currently unavailable due to low sequencing submissions, leaving the panel working from information that is weeks out of date.1
Jill Roberts, associate professor at the University of South Florida College of Public Health, attributed the reduced sequencing to the loss of government surveillance staff and cuts to academic research funding, structural changes that are making real-time tracking of variant evolution harder to sustain.2
What are vaccine makers saying?
All four manufacturers of FDA-approved Covid vaccines indicated readiness to move quickly on an updated formulation. Moderna says it is prepared to supply the recommended composition by mid-August, while Pfizer and BioNTech say they are ready to supply an updated formula upon approval.1
Sanofi, which partners with Novavax on a protein-based shot that takes longer to manufacture than mRNA vaccines, says it is already manufacturing XFG-targeting vaccines for the 2026-2027 season.2
The advisory committee meeting comes after a prolonged period of uncertainty for U.S. vaccine policy. A court placed
Sources
- FDA advisers to weigh composition of COVID vaccines for 2026-2027 Reuters May 28, 2026
https://www.reuters.com/legal/litigation/fda-advisers-weigh-composition-covid-vaccines-2026-2027-2026-05-28/ - US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant Reuters May 26, 2026
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-weigh-updating-2026-27-covid-vaccines-target-xfg-variant-2026-05-26/
Related Content
